On Friday, the US Food and Drug Administration announced the first-of-its-kind approval of a generic nasal spray for opioid overdose treatment, manufactured by the US branch of Israel’s Teva Pharmaceutical Industries. Teva’s drug is the first generic product to receive final approval that does not require medical training to use. Commonly known as Narcan, the spray is considered a life-saving medication. The FDA stated it is working towards approving other generic products for the treatment of opioid overdose.
Recent comments